he long QT syndrome (LQTS) is an inherited arrhythmogenic disease of the structurally normal heart that may cause sudden death. LQTS is characterized by an abnormality in myocardial repolarization that leads to prolongation of the QT interval, morphological changes in T waves and torsades-de-pointes (Tdp) type of ventricular tachycardia on surface ECGs. 1,2 To date, 8 distinct genes responsible for LQTS have been identified, including those of Andersen (LQT7) and Timothy (LQT8) syndromes: on chromosome 11q15.5 (KCNQ1; LQT1), 7q35-36 (KCNH2; LQT2), 3p21 (SCN5A; LQT3), 4q25-27 (ANKB; LQT4), 21q22 (KCNE1; LQT5), 21q22 (KCNE2; LQT6), 17q23 (KCNJ2; LQT7) and 12p13.3 (CACN1C; LQT8). [3] [4] [5] [6] [7] [8] [9] [10] Moss et al 11 extensively examined the relationships between the site of mutation and clinical phenotype in approximately 44 different LQT2-related KCNH2 mutations. They reported that subjects with causative mutations in the pore region (n=38, amino acid residues 550 through 650) had more severe clinical manifestations and experienced a higher frequency (74% vs 35%; p<0.001) of arrhythmia-related cardiac events occurring at younger age than did subjects with non-pore mutations (n=166).
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In LQT1, based on the United States portion of the International LQTS Registry (n=425), the Netherlands' LQTS Registry (n=93), and the Japanese LQTS Registry (n=82), 600 patients with KCNQ1 mutations were classified into 2 groups of patients with transmembrane and C-terminus mutations and their clinical phenotypes were examined. 12 That study found that patients with transmembrane mutations were at increasing risk for cardiac events (hazard ratio, 2.06; p<0.001). Shimizu et al also studied the mutation sitedependent differences in 95 LQT1 patients from a multicenter Japanese population and also found that patients with transmembrane mutations were at higher risk of cardiac events and had longer QTc and Tpeak-end intervals. 13 In Japanese LQT2 patients, mutation site dependency is unclear, although this has been reported in Caucasian patients. Therefore, in the present study we aimed to compare the genotype and phenotype relationship, according to the classification adopted by Moss et al, 11 in 118 Japanese LQT2 patients who were genetically identified in the 3 genetic centers in Japan and had no other mutations in LQTSrelated genes (except LQT4 and 8). 
Mutation Site Dependent Variability of Cardiac

Methods
Study Population
The study population consisted of 118 patients from 69 unrelated Japanese LQT2 families enrolled from 3 institutes in Japan: National Cardiovascular Center, Kyoto University Graduate School of Medicine and Shiga University of Medical Science. The KCNH2 mutations were confirmed in all patients by using standard genetic tests. [14] [15] [16] [17] Screening for mutations in KCNQ1, SCN5A, KCNE1, KCNE2, and KCNJ2 was also conducted, and patients with compound mutations of KCNH2 and/or additional mutations in these LQTS-related genes were excluded from the analysis. Symptomatic patients were defined as KCNH2 mutation carriers who experienced at least 1 episode of syncope (ie, complete loss of consciousness, or cardiac arrest requiring cardiac resuscitation), while asymptomatic patients were those without these events. Follow-up was censored at age 50 years to avoid the influence of coronary artery disease on cardiac events.
Genetic Analysis and Characterization
Genomic DNA was isolated from venous blood by use of the QIAamp DNA blood midikit (Qiagen, Hilden, Germany). The protocol for genetic analysis was approved by the institutional ethics committee and was performed under its guidelines. Established primer settings were used to amplify the entire coding regions of the known LQTS genes from genomic DNA. [14] [15] [16] [17] Denaturing high-performance liquid chromatography (DHPLC) was used for screening. For aberrant conformers, direct sequencing techniques were performed as described elsewhere. 13 PCR products were denatured at 95°C for 5 min then analyzed by DHPLC. PCR fragments presenting abnormal signals in the DHPLC analysis were subsequently sequenced by the dideoxynucleotide chain termination method with fluorescent dideoxynucleotides in an ABI 3130 genetic analyzer (PE Applied Biosystems).
The pore region of the KCNH2 channel was defined as the area extending from S5 to the mid-portion of S6 involving amino acid residues 550 through 650, according to a previous report. 11 The non-pore region included the N-terminus region, transmembrane domains other than the pore region and the C-terminus region.
Clinical Characterization
Routine demographic data and basal 12-lead ECGs were obtained for all subjects at the time of enrollment in each institute and there was at least yearly follow-up contact. All ECGs were taken before or without -blocker medication. The ECG parameters measured from the basal recordings were the RR, QTend, QTpeak and Tpeak-end (QTend-QTpeak) intervals. The latter is thought to reflect the transmural dispersion of ventricular repolarization (TDR). [18] [19] [20] The ratedependent QT intervals were corrected for heart rate by Bazett's method. 21 The QTpeak was defined as the time interval between QRS onset and the peak of the positive T wave or the nadir of the negative T wave. Tpeak-end was then obtained by calculating QTend minus QTpeak.
These parameters were measured manually in lead V5 averaged from 2 or 3 consecutive beats. Bifid T waves other than U waves were included in the QT measurements. If ECG recordings were obtained during a cardiac event, the patients were requested to undergo the examination again after improving. Measurements were performed by 3 investigators who were completely unaware of the patient's clinical and genetic status. There were no significant differences in the measured data between the investigators, and the mean values were used for analysis. LQTS-related cardiac events were defined as syncope, aborted cardiac arrest, or unexpected sudden death.
Statistical Analyses
All data are expressed as the mean value ± SD. The Student's t-test was used to compare continuous data between mutations located in the pore region and those in the non-pore region. Differences in frequencies were analyzed by the chi-square test. Time to the first cardiac event (syncope, cardiac arrest, or sudden cardiac death) before initiation of -blocker therapy and before age 50 years was determined by Kaplan-Meier cumulative estimates. Two-sided probability values <0.05 were considered statistically significant. Statistical calculations were performed with SPSS software (version 11.01J, Chicago, IL, USA). Table 1 lists the KCNH2 mutations we identified, classified by location, number of patients with these causative mutations, coding effects (missense, insertion, deletion and frameshift) and functional outcomes. We identified 62 different KCNH2 mutations among the 69 LQTS families: 42 missense, 16 deletion/insertion, 11 frameshift and 4 nonsense mutations. There were 27 (44%) mutations causing amino acid changes in the pore region and 35 (56%) mutations within the non-pore regions (15 in the N-terminus, 8 in the non-pore transmembrane, and 12 in the C-terminus). In the pore mutations there were 25 (93%) missense mutations and the remaining 2 were protein deletions (K638del and F640del).
Results
Genetic Characteristics
In contrast, the non-pore mutations included more significantly complex mutations such as deletion, insertion, frameshift or nonsense mutations that resulted in truncation of channel proteins (15/35, 43%). Thirty-five mutations (56%, 11 in the pore region and 24 in the non-pore regions) were novel and indicated by asterisk in Table 1 . Functional effects by cellular electrophysiologic tests have been reported in only 12 of the 62 mutations (19%); [22] [23] [24] [25] [26] [27] [28] [29] however, all those previous reports indicated that the KCNH2 mutations had loss-of-function effects and made the IKr current reduce or disappear. Four pore mutations had dominant-negative effects, 4 pore mutations and 2 non-pore mutations had trafficking defects, and 2 non-pore mutations reduced the IKr current. Table 2 is a comparison of the clinical characteristics of the 56 patients with pore mutations and the 62 patients with non-pore mutations. There were no significant differences between the 2 groups regarding gender, the percentage of probands and the age at baseline ECG recording. Diagnostic LQTS scores of Schwartz et al 30 were noticeably greater in the pore group. RR and QTpeak intervals were comparable; however, corrected QTend and Tpeak-end intervals were much longer in the pore than in the non-pore group. Although the incidence of TdP and T-wave alternans did not differ between groups, notched T waves were more frequently seen in the pore group (p=0.007 vs non-pore group). The incidence of cardiac events and the introduction of -blocker therapy were not statistically different between the 2 groups. Fig 1A shows the Kaplan-Meier cumulative cardiac event-free survival curves from birth through to age 50 years for 118 patients (pore group, n=56; non-pore group, n=62). The pore-group patients experienced their first cardiac event at a younger age than the non-pore group (log-rank, p= Fig 1. (A) Kaplan-Meier cumulative cardiac event-free survival curves from birth through to age 50 years for the total of 118 patients with KCNH2 mutations located in the pore (n=56, smooth line) and non-pore (n=62, dotted line) regions. The pore group patients experienced their first cardiac event at a younger age than the non-pore group (log-rank, p=0.049). The difference was caused mainly by the high firstevent rate in non-probands. Kaplan-Meier cumulative cardiac event-free survival curves for 67 probands (B) and 51 non-probands (C) with pore mutations (smooth line) and non-pore mutations (dotted line).
Clinical Characteristics
Clinical Course by Mutation Location
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0.049). We examined the clinical course of the 67 probands and 51 non-probands separately (Figs 1B,C) . The clinical courses of the probands were not significantly different according to mutation site (Fig 1B) , whereas in the non-pore group 28 non-probands remained asymptomatic and more than half had suffered from cardiac events by the age of 50 (Fig 1C) . Therefore, the difference stemmed from markedly distinct prognoses among the non-probands. Table 3 summarizes the clinical characteristics of the 51 non-probands. The absolute and corrected QTend and Tpeak-end intervals were all significantly greater in the pore than in the non-pore group. In the non-probands, the incidence of all cardiac events, syncope, and -blocker therapy were significantly greater in the pore group than in the nonpore group.
Discussion
This study demonstrates that the clinical features of 118 Japanese LQT2 patients who had 62 different KCNH2 mutations correlated with the mutation sites, but only in nonprobands. In probands, there was no significant relationship between mutation site and prognosis. Moss et al 11 reported approximately 179 LQT2 patients based on 44 different KCNH2 mutations and those patients with pore mutations had significantly (p<0.0001) higher frequency of LQTSrelated cardiac events and longer QTc intervals than those with non-pore mutations. In contrast to their results, in the present study the mutation-dependent difference in prognosis was relatively small, though significant (p=0.049), when analyzed in the total patient cohort (Fig 1A) . Indeed, the beneficial outcome of the non-pore patients stemmed from their family members (Fig 1C) , and probands showed virtually similar prognosis to that of pore mutation carriers. Although Moss et al did not report separate sub-analysis of probands and family members, the percentage of family members in their non-pore group was significantly larger than that of the pore group (84% vs 57%, p<0.001). The very good prognosis of the non-pore mutation group in their study may have reflected that large number of family members.
The character of the mutation per se may be important as another reason for the variance between these 2 studies, as both had a similar number of LQT2 patients. Compared with the study by Moss et al, 11 the type of mutation in the present study was quite different: in our non-pore group, there were significantly more complex mutations, such as nonsense or frameshift, that caused the truncation of channel proteins (15/35, 43%) than in the report of Moss et al (4/30, 13%) . For example, nonsense-mediated mRNA decay (NMD) has recently been reported to play an important role in reducing dominant negative suppression effects. 31 Premature termination codon caused by either a deletion or insertion mutation would also cause NMD and thereby attenuate the severity of cardiac phenotypes. This different nature of the mutations may cause the apparently different prognosis of the non-pore mutation groups in each study.
In our pore site mutation group, there were only 2 inframe deletions, but no frameshift mutations (Table 1) . Although it was practically very difficult to conduct every functional assay for each novel KCNH2 mutation identified here, some cellular electrophysiological effects are available in a small number of KCNH2 mutations we found (Table 1) . Several missense mutations in the pore region (such as A561V and T613M) have been shown to produce dominant negative suppression effects, a greater functional change predisposing to arrhythmic events. In contrast, functional assay of several missense mutations in the non-pore regions has revealed relatively smaller loss-of-function effects (such as with A490T or S818L) Greater functional disruption may also be reflected in the different prognosis Table 2 .
of family members in the pore and non-pore groups (Fig 1) . Previously we reported that LQT1 patients with KCNQ1 mutations located in the transmembrane regions, including the pore region, are at a higher risk of congenital LQTS-related cardiac events and longer QTc and Tpeak-end intervals than are patients with C-terminal mutations. 13 In LQT2, we have also demonstrated that Tpeak-end, representing transmural dispersion of ventricular repolarization, 19 is longer in pore patients than in non-pore patients (Table 2) , supporting the finding that family members with pore mutations are more likely to suffer from LQTS-related cardiac events than those with a non-pore mutation.
Study Limitations
Cardiac events are not simply linked to the site of mutation in probands; there are other triggering factors such as modifier genes, including single nucleotide polymorphisms, 32 hypokalemia and bradycardia, which play significant roles in aggravating the symptoms of KCNH2 mutation carriers. The influence of these factors could be interpreted in the similar occurrence of cardiac events in the probands irrespective of mutation site, because the presence of symptoms usually caused the patient to agree to undergo genetic testing.
Regarding each mutation, the number of study patients was relatively small (at most 5), and the location of the mutations was scattered, even in the same pore region. The coding effect was also so various that we had limited ability to show arrhythmic risk according to a specific mutation site. Our cohort contained 35 novel KCNH2 mutations, and their functional outcomes were not available. Moreover, our study population included only Japanese, so more subjects per mutation and a greater spectrum of KCNH2 mutations in a worldwide study are needed to evaluate the arrhythmic risks associated with these mutations.
